Izvorni znanstveni članak
https://doi.org/10.20471/LO.2019.47.02-03.10
Assessment of nutritional risk in cancer patients treated with systemic antineoplastic treatment
Petra Lepetić
orcid.org/0000-0003-0009-5217
; Department of Medical Oncology, Division for Radiotherapy and Medical Oncology, University Hospital for Tumors Zagreb, Sestre milosrdnice University Hospital Center, Zagreb, Croatia;
Ana Tečić-Vuger
; Department of Medical Oncology, Division for Radiotherapy and Medical Oncology, University Hospital for Tumors Zagreb, Sestre milosrdnice University Hospital Center, Zagreb, Croatia;
Mirjana Pavlović
; Department of Medical Oncology, Division for Radiotherapy and Medical Oncology, University Hospital for Tumors Zagreb, Sestre milosrdnice University Hospital Center, Zagreb, Croatia;
Ljubica Vazdar
; Department of Medical Oncology, Division for Radiotherapy and Medical Oncology, University Hospital for Tumors Zagreb, Sestre milosrdnice University Hospital Center, Zagreb, Croatia;
Martina Šepetavc
; Farmacia, Community Pharmacies Chain, Zagreb, Croatia
Robert Šeparović
; Department of Medical Oncology, Division for Radiotherapy and Medical Oncology, University Hospital for Tumors Zagreb, Sestre milosrdnice University Hospital Center, Zagreb, Croatia;
Sažetak
This study aims to explore if there is a change in nutritional risk and body mass index (BMI) in cancer patients during the systemic antineoplastic treatment. We retrospectively analyzed data collected from 216 cancer patients treated at the Department of Medical Oncology, University Hospital for tumors, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia, with systemic antineoplastic therapy in the period from 05/2016 to 05/2018. In our study, we included both patients treated with systemic therapy for the first time and patients treated repeatedly (only patients who have had at least six months free period after the last treatment course were eligible). We included male and female patients with breast cancer, colorectal cancer, pancreatic cancer, and head and neck cancer. Around 75% of patients had metastatic disease. We analyzed data collected from Nutritional Risk Score-2002 (NRS-2002) screening and results of BMI, at first hospitalization, and after three months of systemic antineoplastic treatment. All patients at high nutritional risk (NRS 3-4) received the nutritional intervention, which included enteral nutritional supplement and education of patient and patient’s family about nutrition in oncological patients. We used the Wilcoxon test for the NRS score and t-test for a depended variable for BMI data. The initial average BMI of all patients was 26,45 kg/m². Of all screened patients, around 78% of them were at mild nutritional risk (NRS 1-2), while around 22% of them were at high nutritional risk (NRS 3-4). We recorded a statistically significant decrease both in NRS of the entire screened population of patients after three months of systemic antineoplastic treatment and after specific nutritional intervention in high-risk patients (most patients were at mild nutritional risk, while less than 8% of them were at high nutritional risk). There was no significant change in BMI in the observed period (average BMI was 26, 59 kg/m²). It seems, systemic antineoplastic treatment, along with early nutritional intervention with enteral nutritive supplementation and education, can significantly contribute to the decrease of the nutritional risk.
Ključne riječi
nutritional risk (NR); body mass index (BMI); systemic antineoplastic treatment
Hrčak ID:
233612
URI
Datum izdavanja:
28.1.2020.
Posjeta: 1.311 *